Leukemia inhibitory factor (LIF): A "pleiotropic regulator" of cell fate

Leukemia Inhibitory Factor (LIF) is a multifunctional cytokine belonging to the IL-6 family, but its functions extend far beyond what its name suggests. Unlike cytokines that primarily act on mature immune cells, LIF's core function lies in regulating cellular "fate decisions" — maintaining the pluripotency of embryonic stem cells, determining the differentiation direction of neural cells, modulating reproductive and implantation processes, and playing complex roles in tissue repair and inflammation. It acts like a "dispatcher" working across multiple developmental and physiological pathways, issuing critical instructions in different tissue microenvironments that determine cell survival, proliferation, differentiation, or dedifferentiation.

LIF can be produced by various cells, including stromal cells, fibroblasts, trophoblast cells, activated T cells, and certain tumor cells. It is a glycoprotein with a molecular weight of approximately 38-45 kDa, named after its initial discovery as a factor capable of inducing the differentiation of murine myeloid leukemia M1 cells into non-proliferative macrophages.

LIF exerts its effects through a high-affinity receptor complex, the unique composition of which determines the breadth and complexity of its signaling.

High-affinity receptor complex: Composed of the LIF-specific receptor α-chain (LIFRα, also known as LIFR or gp190) and the signal transducer gp130. LIF first binds to LIFRα, then recruits and dimerizes gp130 to form a heterodimeric complex, initiating downstream signaling.

Receptor sharing and functional differentiation: gp130 is a common signal transducer for cytokines in the IL-6 family (such as IL-6, IL-11, Oncostatin M (OSM), Ciliary Neurotrophic Factor (CNTF), etc.). This sharing mechanism explains the partial functional overlap among IL-6 family members. However, the specific pairing with LIFRα endows LIF with unique biological effects, particularly in embryonic stem cells and the nervous system.

Regulation by soluble receptors: Soluble LIFR (sLIFR) exists and can bind to LIF, neutralizing its activity, which is an important physiological regulatory mechanism.

LIF's core function is to act as an "environmental signal decoder," translating extracellular microenvironmental instructions into intracellular signals that determine cell fate.

The "lifeline" of mouse ESCs: In in vitro culture of mouse embryonic stem cells, LIF, through activation of the STAT3 signaling pathway, is a key factor in maintaining their undifferentiated state, self-renewal capacity, and pluripotency. Without LIF, mouse ESCs spontaneously differentiate.

The core mechanism: STAT3 activation: LIF/gp130 signaling continuously activates STAT3, which translocates to the nucleus and upregulates the expression of core pluripotency transcription factors (such as Klf4, Nanog, Sox2) while suppressing differentiation-related genes. This is LIF's most iconic function in mouse stem cell biology.

Differences in human ESCs: Unlike mice, human pluripotent stem cells (hPSCs) primarily rely on the Activin/Nodal-SMAD2/3 and FGF signaling pathways for self-renewal, with LIF being non-essential. This species difference is a critical point in stem cell research.

Promoting neuronal survival and differentiation: LIF is an important neurotrophic factor that promotes the survival of cholinergic neurons, sensory neurons, and motor neurons, and influences their neurotransmitter phenotype expression.

Involvement in glial cell fate: Under injury or disease conditions, LIF can induce neural precursor cells to differentiate into astrocytes rather than oligodendrocytes, a process termed "glial fate bias," which plays a significant role in neural repair and glial scar formation.

Influencing synaptic plasticity and pain: In the adult nervous system, LIF participates in regulating synaptic function and the generation of chronic neuropathic pain.

Key mediator of uterine receptivity: During the implantation window, endometrial epithelial cells express LIF abundantly. LIF is crucial for the transition of the endometrium to a "receptive state" capable of accepting embryo implantation. Female mice with LIF gene knockout exhibit infertility due to the inability of embryos to implant.

A marker for reproductive disorders: Insufficient endometrial LIF expression is closely associated with unexplained infertility and recurrent implantation failure in humans.

Inhibiting osteoblast differentiation: In the skeletal system, LIF inhibits the differentiation of mesenchymal stem cells into osteoblasts, thereby potentially affecting bone formation.

Regulating fat metabolism: LIF can influence adipocyte differentiation and function, participating in energy metabolism regulation.

Upon binding to its receptor, LIF primarily activates three classical downstream signaling pathways, with effects depending on cell type and microenvironmental context.

JAK-STAT3 pathway (core pathway, especially in stem cells):

JAK1/JAK2/Tyk2-STAT3 activation: After receptor dimerization, the JAK kinases (JAK1, JAK2, Tyk2) coupled with gp130 and LIFRα are activated. Activated JAK phosphorylates the intracellular segment of the receptor, providing a docking site for STAT3.

The central role of STAT3: Phosphorylated STAT3 dimers translocate to the nucleus, directly regulating genes related to pluripotency, survival, and anti-apoptosis. This is the primary pathway through which LIF maintains pluripotency in mouse ESCs.

MAPK/ERK pathway:

Activation of the Ras-MAPK cascade via adapter proteins Shc and Grb2. In stem cells, ERK signaling typically promotes differentiation, forming a delicate balance or antagonism with STAT3's self-renewal signals. This "STAT3 vs. ERK" balance determines whether stem cells maintain pluripotency or initiate differentiation programs.

PI3K-Akt pathway:

Primarily mediates cell survival, metabolism, and growth signals. Akt activation promotes cell survival and counteracts apoptosis, playing a significant role in various protective effects mediated by LIF.

Dysregulation of LIF expression and signaling is associated with various developmental, reproductive, neurological, and tumor-related diseases.

Unexplained infertility and recurrent implantation failure: As mentioned earlier, deficient endometrial LIF expression is an important etiological factor. Detecting endometrial LIF expression has become an assessment metric in reproductive medicine.

Potential therapeutic applications: In assisted reproductive technology (ART), studies have attempted exogenous supplementation of recombinant LIF (e.g., intrauterine perfusion) during embryo transfer cycles to improve endometrial receptivity and increase implantation rates, though efficacy still requires validation through large-scale clinical trials.

Neurodegenerative diseases: In conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), upregulated LIF expression may represent an endogenous protective response aimed at promoting neuronal survival and glial cell repair. Thus, strategies involving exogenous LIF or enhancing its signaling pathways are being explored as neuroprotective therapies.

Spinal cord injury: After injury, LIF is rapidly upregulated, promoting astrocyte proliferation and glial scar formation to limit damage spread, but it may also inhibit axonal regeneration, exhibiting a dual role.

A complex and contradictory "double-edged sword" role:

Pro-tumor effects: In certain cancers (e.g., breast cancer, ovarian cancer, glioblastoma), LIF can promote tumor cell proliferation, survival, stemness, metastasis, and chemotherapy resistance by activating STAT3 and AKT pathways. Tumor-derived LIF can also remodel the tumor microenvironment and suppress anti-tumor immunity. Consequently, anti-LIF neutralizing antibodies are being investigated as novel anticancer agents in preclinical and early clinical studies.

Anti-tumor effects: In myeloid leukemia (as initially discovered), LIF can inhibit cancer cell proliferation and induce differentiation.

Regulatory role: LIF possesses anti-inflammatory properties, inhibiting macrophage overactivation and potentially inducing regulatory T cells. In diseases like rheumatoid arthritis, it may exert protective effects.

May participate in osteoporosis pathology by inhibiting osteogenesis, though its specific role requires further investigation.

A deeper understanding of LIF's pleiotropic functions is driving its application in several cutting-edge fields.

Optimizing stem cell culture systems: In preparing induced pluripotent stem cells (iPSCs) for cell therapy or disease modeling, the rational use of LIF signaling (especially for mouse-derived cells) remains key to maintaining high-quality pluripotent stem cells.

Tissue engineering and repair: Leveraging LIF's neurotrophic and reparative properties, integrating it into biomaterials or cell therapies for treating spinal cord injuries, neurodegenerative diseases, etc.

LIF as a novel immunotherapy target: Given LIF's pivotal role in shaping an immunosuppressive tumor microenvironment, targeting LIF (using neutralizing antibodies or receptor antagonists) could be combined with existing immune checkpoint inhibitors (e.g., anti-PD-1/L1) to "reverse" immunosuppression and activate anti-tumor immunity, particularly in "cold tumors." Related drugs have entered clinical trials.

Biomarker: Detecting LIF levels in tumor tissue or blood may help predict patient response to specific treatments (especially immunotherapy) or prognosis.

Based on precise detection of endometrial LIF expression, individualized LIF supplementation for deficient patients is a promising direction to improve the success rate of assisted reproduction.

Developing LIF analogs or small-molecule agonists capable of crossing the blood-brain barrier to provide new therapeutic approaches for ALS, stroke, and other diseases.

Leukemia Inhibitory Factor is a "pleiotropic master" that transcends its original nomenclature. It is not only the "guardian" of embryonic stem cells but also the "coordinator" of the nervous and reproductive systems, and an emerging "regulatory hub" in the tumor microenvironment. Its functions are highly dependent on specific cellular contexts and tissue microenvironments, perfectly illustrating the cellular biological principle of "context determines fate." From a basic tool for maintaining stem cell pluripotency in laboratories to an indicator for assessing endometrium in fertility clinics, and now a spotlighted new target in tumor immunotherapy, research on LIF continues to bridge the boundaries of basic science, clinical medicine, and biotechnology. In the future, with deeper insights into its complex signaling networks and disease-specific roles, precise modulation of LIF signaling will bring revolutionary advances to stem cell therapy, cancer immunotherapy, neural repair, reproductive medicine, and a host of other fields.